<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333967</url>
  </required_header>
  <id_info>
    <org_study_id>AHAT-104</org_study_id>
    <nct_id>NCT03333967</nct_id>
  </id_info>
  <brief_title>The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province</brief_title>
  <official_title>The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Anhui Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct the real world study to explore the efficacy and safety of Apatinib
      in gastric cancer .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>1year</time_frame>
    <description>Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>1year</time_frame>
    <description>Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3year</time_frame>
    <description>overall survival is defined as the length of time from random assignment to death or to last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Disease-free survival is defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life score</measure>
    <time_frame>1year</time_frame>
    <description>Quality of life score is a questionnaire developed to assess the quality of life of cancer patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>1year</time_frame>
    <description>adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.</description>
  </other_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Gastric Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients of gastric cancer in Anhui province
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients .

          2. Confirmed by Pathology or histology of Gastric cancer

          3. Patients should be voluntary to the trial and provide with signed informed consent

          4. The researchers believe patients can benefit from the study.

        Exclusion Criteria:

          1. Patients with a known history of allergic reactions and/or hypersensitivity attributed
             to apatinib or its accessories

          2. Pregnant or lactating women

          3. Patients with Apatinib contraindications

          4. Patients of doctors considered unsuitable for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>China Anhui</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Anhui Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>guoping sun, doctor</last_name>
    <phone>0551-62922249</phone>
    <email>gpsun_ahmu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoping Sun, doctor</last_name>
      <phone>0551-62922249</phone>
      <email>gps_anmu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

